ValiRx PLC - Directorate Changes and new Advisory Board

This RNS details the outcomes of the operational review initiated in Q4 2024. The review was implemented to identify improvements in operational efficiency and reduce company overheads as we move forward and includes changes at the board and employee level as well as creating a new Advisory board. We have reduced the head count by three to a team of just nine people comprising three staff in Inaphaea, three staff in ValiRx, including our CEO, and three other board members including our Chairman, financial Director and a new NED. The changes have delivered a saving of £170, 000 per year in salaries equivalent to around £200, 000 with employer NI and pension contributions.